 Cortexyme, Inc. Nasdaq: CRTX, a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimers AD and other degenerative diseases, today announced the publication of research further documenting the ability of the pathogen Porphyromonas gingivalis to invade neurons and trigger Alzheimers-like neuropathology. The findings are to be published in the June 2020 issue of the Journal of Alzheimers Disease JAD 754; an early online version of the paper is available now so that the important findings can be rapidly disseminated to the research community. 